Korea's GLP-1 Breakthrough Could Split the Obesity Drug Duopoly in

A Korean drug takes on the world’s biggest pharma duopoly

South Korea’s food and drug regulator approved Hanmi Pharmaceutical’s epeglunatide — branded as “Epe” — on October 7, clearing the way for the country’s first domestically developed GLP-1 obesity treatment to reach patients. The timeline is aggressive: Hanmi is aiming for a market launch as early as late October, compressing what normally takes three months after approval down to under four weeks.

The drug comes in five strengths, from 2 mg to 10 mg, as a once-weekly injection. It works by targeting GLP-1 receptors in the brain and gastrointestinal tract to suppress appetite and slow gastric emptying — the same general mechanism as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, which have essentially split the South Korean market between them.

What makes this approval notable goes well beyond Korea’s borders.

The pricing bombshell

Wegovy costs Korean patients roughly 200,000 to 400,000 won per month, depending on dose. Mounjaro runs 300,000 to 600,000 won. Epe is expected to land around 200,000 won monthly — possibly lower in its initial phase, with some market rumors pointing toward a launch price closer to 120,000 won.

This is not incremental competition. This is a structural price disruption in a market where the two drugs together generated over 9.6 billion won in the first half of 2026 alone. Mounjaro led with 7.44 billion won; Wegovy pulled in 2.17 billion won. For context, Mounjaro’s first-half sales already put it on track to break the 10 billion won annual milestone — a figure no domestically made GLP-1 in Korea has ever approached.

The pricing strategy is deliberate. In Korea’s non-insured drug market, where out-of-pocket cost directly drives prescription behavior, every 10,000 won matters. Hanmi is betting that price sensitivity among Korean consumers — many of whom have been waiting months or years for reliable access to GLP-1 treatments — will fracture the duopoly fast.

A different clinical story

Epe isn’t just a cheaper copy. It underwent its own Phase 3 program with 448 Korean adults who were obese or overweight but did not have diabetes. At 40 weeks, the average weight reduction was 9.75 percent. Nearly 80 percent of patients lost more than 5 percent of their body weight, and about half shed more than 10 percent. Among women with a BMI under 30, the average drop reached 12.2 percent.

Those numbers are credible for a first entrant, even if head-to-head data against Wegovy or Mounjaro doesn’t yet exist. What’s strategically sharper is that the data comes from a Korean patient population — something neither Novo Nordisk nor Eli Lilly can claim with the same specificity for their products in Korea. Hanmi is using this to court Korean physicians who have grown frustrated with prescribing imported drugs whose dosing and safety profiles were calibrated for Western bodies.

The supply chain play

Here is where the regional implications deepen. Both Wegovy and Mounjaro are manufactured overseas and imported into Korea. Supply shortages have been a recurring theme across Asia, with patients in Japan, China, and India facing months-long waits or being forced into gray-market channels.

Hanmi is producing Epe at its bioprocess facility in Pyeongtaek, capable of up to 20 million pre-filled syringes annually. That is domestic supply, insulated from the kind of international logistics disruptions that have plagued competitors. In a region where patients have learned to treat drug availability as an intrinsic part of the treatment’s value proposition, that reliability is worth more than the sticker price.

If the Pyeongtaek plant proves it can sustain that output without quality issues — a significant if, given the complexity of GLP-1 peptide manufacturing — Hanmi could eventually supply not just Korea but neighboring markets where domestic production capacity remains virtually nonexistent.

Why Japan and China are watching

Japan has been far more cautious than South Korea in approving GLP-1 obesity indications. Novo Nordisk’s Saxenda received approval there in 2022, but Mounjaro and Wegovy are still awaiting full obesity approvals, caught in a slower regulatory review process that prioritizes safety signals over speed. A successful Korean launch — especially one that demonstrates real-world effectiveness in an East Asian population — could provide the clinical argument Japanese regulators and payers have been waiting for.

China presents a different picture. Domestic players like Hansoh Pharma and Simcere Pharma are developing their own GLP-1 candidates, and the Chinese market is already seeing aggressive pricing from local manufacturers. But none have reached commercialization at scale yet. Korea’s regulatory timeline — a domestic GLP-1 reaching patients within weeks of approval — sets a benchmark that Chinese regulators and companies will measure themselves against.

India, still largely dependent on imports for branded GLP-1 therapies, stands to benefit if the Korean model proves replicable. A regional manufacturing hub in Korea could, in theory, serve Indian patients at a fraction of current costs — though regulatory hurdles and local production capacity remain significant barriers.

The digital wrapper

Hanmi is also positioning Epe as Korea’s first digital-combined medicine, attaching a platform intended to track diet, exercise, and lifestyle changes alongside the injection. This mirrors a broader industry push to differentiate GLP-1 products through digital support services rather than chemistry alone. Whether the platform meaningfully improves outcomes or functions as marketing theater remains to be seen — but it signals that Hanmi understands the Korean market wants more than a pill or a shot.

What happens next

The next three months will be telling. If Epe captures even 15 to 20 percent of the Korean GLP-1 obesity market at its price point, the duopoly’s pricing power weakens regionally. Novo Nordisk and Eli Lilly will face pressure to adjust — or accelerate their own regional manufacturing strategies to compete on availability as well as efficacy.

A Korean success story also changes the calculus for regulatory agencies in Tokyo, Beijing, and New Delhi. Proving that a domestically developed, lower-cost GLP-1 can achieve strong commercial uptake in an East Asian population gives those regulators ammunition to speed their own approvals and give their local industries room to compete.

For patients across Asia who have been priced out or stuck on waiting lists, the arrival of Epe is not a revolution. But it is the first crack in a wall that has felt impenetrable.